Tumor Biology

, Volume 36, Issue 4, pp 2523–2529 | Cite as

Serum IL-17F combined with VEGF as potential diagnostic biomarkers for oral squamous cell carcinoma

  • Liang Ding
  • Er-Ling Hu
  • Yu-Jun Xu
  • Xiao-Feng Huang
  • Dong-Ya Zhang
  • Bing Li
  • Qin-Gang Hu
  • Yan-Hong Ni
  • Ya-Yi Hou
Research Article

Abstract

Although interleukin (IL) 17A can promote angiogenesis in several tumors, there are limited clinical evidences on cancer about the correlation between serum vascular endothelial growth factor (VEGF) and IL-17F, which is the most homologous to IL-17A. In this study, serum concentration of IL-17F and VEGF from healthy (n = 28), leukoplakia (n = 15), and oral squamous cell carcinoma (OSCC) groups (n = 85) were assessed and showed that IL-17F level was remarkably downregulated from healthy group (394.3 pg/ml) to OSCC group (82.96 pg/ml). Conversely, the OSCC group had a highest level of VEGF (P < 0.05) in whole groups, and there was a negative correlation between IL-17F and VEGF in serum or in the peripheral blood mononuclear cells (PBMCs) at mRNA level. Moreover, the lowest ratio of IL-17F/VEGF was found in OSCC patients (P < 0.05) and lower ratio of IL-17F/VEGF correlated to higher tumor stage and lymph node metastasis. Furthermore, the serum level of IL-17F and the ratio of IL-17F/VEGF were positively associated with the numbers of CD3+ CD4+ T cells, which indicated that serum IL-17F could originate from PBMCs during the development of OSCC, and could be used for the diagnosis by effectively distinguishing OSCC patients from healthy individuals.

Keywords

IL-17F VEGF Oral squamous cell carcinoma CD4+ T cells Diagnosis 

Notes

Acknowledgments

This work was supported by a grant from the National Natural Science Foundation of China (No. 81402238, 81072213 and 81271698), the Nanjing Medical Science & Research Project (No.YKK11039, YKK13145), Nanjing Medical Young Engineer (QRX113311), National Key Disciplines Constructional Project Funding (Since 2011), Jiangsu Provincial Clinical Medicine of Science and Technology project (Grant No BL2012017), Nanjing Municipal Key Medical Laboratory Constructional Project Funding (Since 2012), and Center of Nanjing Clinical Medicine of tumor project (since 2014).

Authors’ contributions

L.D., YH.N. and YY.H. designed experiments with valuable help from XF.H., EL.H., and QG.H. L.D. performed and analyzed data with valuable help from EL.H. and YJ.X. L.D. and DY.Z. wrote the manuscript. XF.H and B.L. collected surgical specimens; YY.H. and YH.N. oversaw the overall project.

Conflicts of interest

None

References

  1. 1.
    Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995;155(12):5483–6.PubMedGoogle Scholar
  2. 2.
    Kawaguchi M, Onuchic LF, Li XD, Essayan DM, Schroeder J, Xiao HQ, et al. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol. 2001;167(8):4430–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929–39. doi: 10.1002/art.27334.CrossRefPubMedGoogle Scholar
  4. 4.
    Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008;14(3):275–81. doi: 10.1038/nm1710.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol. 2009;10(7):778–85. doi: 10.1038/ni.1741.CrossRefPubMedGoogle Scholar
  6. 6.
    Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205(5):1063–75. doi: 10.1084/jem.20071978.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wang L, Jiang Y, Zhang Y, Wang Y, Huang S, Wang Z, et al. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS One. 2012;7(3):e34400. doi: 10.1371/journal.pone.0034400.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Melton AC, Melrose J, Alajoki L, Privat S, Cho H, Brown N, et al. Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation. PLoS One. 2013;8(3):e58966. doi: 10.1371/journal.pone.0058966.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620–7. doi: 10.1182/blood-2002-05-1461.CrossRefPubMedGoogle Scholar
  10. 10.
    Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 2005;175(9):6177–89.CrossRefPubMedGoogle Scholar
  11. 11.
    Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE, et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol. 2001;167(8):4137–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Xie Y, Sheng W, Xiang J, Ye Z, Yang J. Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Investig. 2010;28(6):598–607. doi: 10.3109/07357900903287030.CrossRefGoogle Scholar
  13. 13.
    Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One. 2012;7(4):e34959. doi: 10.1371/journal.pone.0034959.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sathish N, Wang X, Yuan Y. Human papillomavirus (HPV)-associated oral cancers and treatment strategies. J Dent Res. 2014;93(7 suppl):29S–36. doi: 10.1177/0022034514527969.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Li C, Zhao Y, Zhang W. Increased prevalence of T(H)17 cells in the peripheral blood of patients with head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(1):81–9. doi: 10.1016/j.tripleo.2010.11.032.CrossRefPubMedGoogle Scholar
  16. 16.
    Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149–62. doi: 10.1016/j.immuni.2011.02.012.CrossRefPubMedGoogle Scholar
  17. 17.
    Maniati E, Soper R, Hagemann T. Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene. 2010;29(42):5653–62. doi: 10.1038/onc.2010.367.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999;59(15):3698–704.PubMedGoogle Scholar
  19. 19.
    Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM, Silva JS. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol. 2013;43(6):1518–28. doi: 10.1002/eji.201242951.CrossRefPubMedGoogle Scholar
  20. 20.
    Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology. 2010;51(1):154–64. doi: 10.1002/hep.23291.CrossRefPubMedGoogle Scholar
  21. 21.
    Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, et al. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One. 2011;6(3):e18219. doi: 10.1371/journal.pone.0018219.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut. 2008;57(6):772–9. doi: 10.1136/gut.2007.123794.CrossRefPubMedGoogle Scholar
  23. 23.
    Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev. 2010;21(6):413–23. doi: 10.1016/j.cytogfr.2010.10.002.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Quan Y, Zhou B, Wang Y, Duan R, Wang K, Gao Q, et al. Association between IL17 polymorphisms and risk of cervical cancer in Chinese women. Clin Dev Immunol. 2012;2012:258293. doi: 10.1155/2012/258293.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wu X, Zeng Z, Chen B, Yu J, Xue L, Hao Y, et al. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer J Int du Cancer. 2010;127(1):86–92. doi: 10.1002/ijc.25027.CrossRefGoogle Scholar
  26. 26.
    Xu C, Hao K, Yu L, Zhang X. Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer. Biomarkers Biochem Indic Expo Response Susceptibility to Chem. 2014;19(4):287–90. doi: 10.3109/1354750X.2014.908954.Google Scholar
  27. 27.
    Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2010;69(3):348–54. doi: 10.1016/j.lungcan.2009.11.013.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Liang Ding
    • 1
  • Er-Ling Hu
    • 1
  • Yu-Jun Xu
    • 1
  • Xiao-Feng Huang
    • 2
  • Dong-Ya Zhang
    • 1
  • Bing Li
    • 2
  • Qin-Gang Hu
    • 2
  • Yan-Hong Ni
    • 1
  • Ya-Yi Hou
    • 1
  1. 1.Central Laboratory of Stomatology, Hospital of Stomatology, and The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical SchoolNanjing UniversityNanjingChina
  2. 2.Department of Oral and Maxillofacial Surgery, Institute and Hospital of StomatologyNanjing University Medical School, Nanjing Stomatological HospitalNanjingChina

Personalised recommendations